Join us in Okinawa for the 52nd Japanese Society of Toxicology (JSOT) Meeting 2025.
We are looking forward to connecting with the toxicology community to showcase our latest solutions that help organizations streamline their lab operations and accelerate their research.
Our Luncheon Seminar, co-hosted by Instem, Charles River, and Labcorp
Title: The IHI VICT3R Project – Bringing the Concept of Virtual Control Groups to Implementation Introducing the concept of virtual control groups to non-clinical trials
Venue: Hall 2 (Conference Building A)
Date and time: Wednesday, July 2, 2025, 11:45-12:45
Program
11:30 – Session Starts
11:45 – Chairperson’s Opening Remarks, Chairperson: Gen Sato (Eisai Co., Ltd. Global Regulatory Non-Clinical Department)
11:50 – Instem, Speaker: Brenda Finney, PhD
12:10 – Charles River Laboratories, Speaker: William O’Neill, DVM, MPH
12:30 – Labcorp Early Development Laboratories Inc., Speaker: Alok Sharma, BVSc, MVSc, MS, PhD, Diplomate ACVP, DABT
Closing Remarks
Seminar Overview
The VICT3R project is a public-private partnership funded by the European Innovative Health Initiative (IHI) that works to reduce the use of animals in toxicity testing for drug and chemical safety.
VICT3R aims to provide a scientifically sound alternative to control animals through the development of virtual control groups (VCGs) based on curated historical data and advanced statistical and AI approaches.
The aim of VICT3R is to significantly reduce the number of animals used in safety testing by replacing real control groups with “virtual control groups” (VCGs). As around 25% of animals used in drug and chemical safety testing are control groups (groups that do not receive the substance being tested), replacing these with virtual animals has a significant impact on the number of animals used.
The concept of virtual control groups emerged from the IMI2 project eTRANSAFE, which aimed to improve the quality of toxicity testing performed on potential pharmaceuticals before testing in humans. Over the years, pharmaceutical companies and other organizations have accumulated a huge amount of data on control groups in toxicity testing.
eTRANSAFE saw that this data could be leveraged to create virtual control groups. Although the tests have demonstrated the feasibility of the VCG concept, more work is required before it can be put into practical use. VICT3R aims to address the challenges that prevent VCG adoption and to gain regulatory approval for the VCG concept. In this presentation, VICT3R’s latest activities will be presented.
Visit our booth to learn more about our leading software & services including:
Provantis®
Streamlines end-to-end workflows for preclinical study management. Ask about our new Non-GLP Pathology module!
An electronic laboratory notebook (ELN) that simplifies and streamlines the digitization and documentation of lab processes.
SEND Advantage™ Outsourced Services and Consulting
A suite of services that ensure your nonclinical data meets the Standard for Exchange of Nonclinical Data (SEND) submission requirements.
Submit™ Seamless Electronic SEND Submissions
Improves the speed and quality of new pharmaceutical developments by enabling the efficient exchange of critical study data between sponsors, CROs and regulators.
Cyto Study Manager™
Enables improved management of genotoxicity studies, delivering enhanced accuracy, documentation and compliance.
Leadscope Model Applier™
An advanced In Silico toxicology tool that helps scientists predict toxicity endpoints, review results with confidence, and generate regulatory-compliant reports. Ask the team for a demo of our new Toxicity Profiler!
KnowledgeScan™
Technology-enabled Target Safety Assessment service enabling researchers to make smarter, faster, data driven decisions.
Centrus®
This powerful tool consolidates and structures data from various sources into a unified, accessible platform, enabling high-quality data management and seamless data sharing for early-stage research.
Advance™
A comprehensive solution supporting the ICH S1B Weight of Evidence Addendum for assessing carcinogenicity risk. Advance streamlines early-stage safety evaluations, reducing costs, saving valuable time, and minimizing the need for animal testing.
Predict™
Our Predict service uses advanced QSAR techniques to streamline early-stage safety assessments through predictive modeling. Enables researchers to evaluate potential toxicity risks quickly, supporting data-driven decision-making and reducing the need for subject testing.
Contact us to set up a meeting with our onsite team!